The CB2 agonist AM1241, but not JWH-015, increases nuclear Akt immunoreactivity. (A), Treatment of HT22 cells with the CB2 agonist JWH-015 had no effect on nuclear Akt immunoreactivity. Treatment with AM1241, however, led to an increase in nuclear Akt immunoreactivity (red arrows). (B), Treatment of HT22 cells with the CB2 agonists JWH-015 and AM1241 had no effect on nuclear or cytosolic pAkt immunoreactivity. In fact, JWH-015 led to a reduction in pAkt immunoreactivity. For the Akt study, n equals 61, 56 and 59 cells for vehicle, JWH-015 and AM-1241 treatments, respectively. For the pAkt study, n equals 80, 91 and 64 cells for vehicle, JWH-015 and AM-1241 treatments, respectively. A P-value of < 0.01 and ≤ 0.001 is indicated by ** and ***, respectively, as determined by a two-sample t-test. The white scale bar is 25 μm.